Pfizer Reports Long-Term Survival Benefit for BRAFTOVI + MEKTOVI in BRAF V600E-Mutant NSCLC
Pfizer Inc. has reported updated results from the Phase 2 PHAROS trial for BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) in treating metastatic non-small cell lung cancer with the BRAF V600E mutation. The trial showed a median overall survival of 47.6 months for treatment-naïve patients and 22.7 months for previously treated patients, with four-year survival rates of 49% and 31%, respectively. Common adverse events included nausea and fatigue. Results will be presented at the 2025 ESMO Congress and published in the Journal of Clinical Oncology.
Pfizer Inc. has announced updated results from the Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) combined with MEKTOVI® (binimetinib) for adults with metastatic non-small cell lung cancer (mNSCLC) harboring the BRAF V600E mutation. The findings show a median overall survival of 47.6 months in treatment-naïve patients and 22.7 months in previously treated patients. Four-year overall survival rates were 49% for treatment-naïve and 31% for previously treated patients. The most common treatment-related adverse events were nausea, diarrhea, fatigue, and vomiting. These results will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress and have been published in the Journal of Clinical Oncology. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251017611442) on October 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
